Article Information
History
- April 22, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Marek J. Konieczny1,
- Murad Omarov1,
- Rainer Malik1,
- Tom G. Richardson2,3,
- Sebastian-Edgar Baumeister4,
- Jürgen Bernhagen1,5,6b,
- Martin Dichgans1,5,6,6b and
- Marios K. Georgakis1,5,7,*
- 1Institute for Stroke and Dementia Research (ISD), LMU University Hospital, LMU Munich, Munich, Germany
- 2Medical Research Council (MRC) Integrative Epidemiology Unit (IEU), University of Bristol, Bristol, United Kingdom
- 3Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom
- 4Institute of Health Services Research in Dentistry, University of Münster, Münster, Germany
- 5Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
- 6German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- 6bGerman Centre for Cardiovascular Research (DZHK, Munich), Munich, Germany
- 7Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA
- ↵*Corresponding author Materials & Correspondence
Marios K. Georgakis, MD, PhD, Institute for Stroke and Dementia Research Ludwig-Maximilians-University (LMU) Hospital Feodor-Lynen-Str. 17, 81377 Munich, Germany, Tel: +49-89-4400-46154, Fax: +49-89-4400-46040, E-mail: marios.georgakis{at}med.uni-muenchen.de
Posted April 22, 2024.
The Genomic Architecture of Circulating Cytokine Levels Points to Drug Targets for Immune-Related Diseases
